Literature DB >> 33221954

The anti-cancer effect of series of strained photoactivatable Ru(II) polypyridyl complexes on non-small-cell lung cancer and triple negative breast cancer cells.

Christelle Fayad1, Hassib Audi2, Rony S Khnayzer3, Costantine F Daher4.   

Abstract

Ruthenium complexes have been recently reported as potential chemotherapeutic agents that offer tumor selectivity and low tumor resistance. This study investigates the photochemistry and the effect of four strained photoactivatable polypyridyl ruthenium(II) complexes on non-small-cell lung cancer (A549) and triple negative breast cancer (MDA-MB-231) cells. All four ruthenium(II) complexes, [Ru(bpy)2dmbpy]Cl2 (C1) where (bpy = 2,2'-bipyridine and dmbpy = 6,6'-dimethyl-2,2'-bipyridine), [Ru(phen)2dmbpy]Cl2 (C2) where (phen = 1,10-phenanthroline), [Ru(dpphen)2dmbpy]Cl2 (C3) (where dpphen = 4,7-diphenyl-1,10-phenanthroline) and [Ru(BPS)2dmbpy]Na2 (C4) where (BPS = bathophenanthroline disulfonate) eject the dmbpy ligand upon activation by blue light. Determination of the octanol-water partition coefficient (log P) revealed that C3 was the only lipophilic complex (log P = 0.42). LC-MS/MS studies showed that C3 presented the highest cellular uptake. The cytotoxic effect of the complexes was evaluated with and without blue light activation using WST-1 kit. Data indicated that C3 exhibited the highest cytotoxicity after 72 h (MDA-MB-231, IC50 = 0.73 µM; A549, IC50 = 1.26 µM) of treatment. The phototoxicity indices of C3 were 6.56 and 4.64 for MDA-MB-230 and A549, respectively. Upon light activation, C3 caused significant ROS production and induced apoptosis in MDA-MB-231 cells as shown by flow cytometry. It also significantly increased Bax/Bcl2 ratio and PERK levels without affecting caspase-3 expression. C3 exhibited poor dark toxicity (IC50 = 74 μM) on rat mesenchymal stem cells (MSCs). In conclusion, the physical property of the complexes dictated by the variable ancillary ligands influenced cellular uptake and cytotoxicity. C3 may be considered a promising selective photoactivatable chemotherapeutic agent that induces ROS production and apoptosis.

Entities:  

Keywords:  A549; Apoptosis; Cytotoxicity; MDA-MB-231; Photoactivated chemotherapy; Polypyridyl ruthenium(II)

Year:  2020        PMID: 33221954     DOI: 10.1007/s00775-020-01835-7

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  33 in total

1.  Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy.

Authors:  Jessica D Knoll; Claudia Turro
Journal:  Coord Chem Rev       Date:  2015-01-01       Impact factor: 22.315

Review 2.  Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.

Authors:  Gwo Yaw Ho; Natasha Woodward; Jermaine I G Coward
Journal:  Crit Rev Oncol Hematol       Date:  2016-03-24       Impact factor: 6.312

3.  Why develop photoactivated chemotherapy?

Authors:  Sylvestre Bonnet
Journal:  Dalton Trans       Date:  2018-07-06       Impact factor: 4.390

4.  Synthesis, structure and biological evaluation of ruthenium(III) complexes of triazolopyrimidines with anticancer properties.

Authors:  Marzena Fandzloch; Liliana Dobrzańska; Tomasz Jędrzejewski; Julia Jezierska; Joanna Wiśniewska; Iwona Łakomska
Journal:  J Biol Inorg Chem       Date:  2019-11-18       Impact factor: 3.358

5.  Photodynamic inactivation of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus with Ru(II)-based type I/type II photosensitizers.

Authors:  Yaxal Arenas; Susan Monro; Ge Shi; Arkady Mandel; Sherri McFarland; Lothar Lilge
Journal:  Photodiagnosis Photodyn Ther       Date:  2013-08-05       Impact factor: 3.631

6.  Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.

Authors:  Wei Guo; Wei Zheng; Qun Luo; Xianchan Li; Yao Zhao; Shaoxiang Xiong; Fuyi Wang
Journal:  Inorg Chem       Date:  2013-04-15       Impact factor: 5.165

Review 7.  Metals and metal compounds in cancer treatment.

Authors:  Bernard Desoize
Journal:  Anticancer Res       Date:  2004 May-Jun       Impact factor: 2.480

Review 8.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

9.  A highly tumor-specific light-triggerable drug carrier responds to hypoxic tumor conditions for effective tumor treatment.

Authors:  Wooram Park; Byoung-chan Bae; Kun Na
Journal:  Biomaterials       Date:  2015-11-11       Impact factor: 12.479

10.  Combination of Ru(ii) complexes and light: new frontiers in cancer therapy.

Authors:  Cristina Mari; Vanessa Pierroz; Stefano Ferrari; Gilles Gasser
Journal:  Chem Sci       Date:  2015-01-13       Impact factor: 9.825

View more
  3 in total

1.  Light-responsive and Protic Ruthenium Compounds Bearing Bathophenanthroline and Dihydroxybipyridine Ligands Achieve Nanomolar Toxicity towards Breast Cancer Cells.

Authors:  Olaitan E Oladipupo; Spenser R Brown; Robert W Lamb; Jessica L Gray; Colin G Cameron; Alexa R DeRegnaucourt; Nicholas A Ward; James Fletcher Hall; Yifei Xu; Courtney M Petersen; Fengrui Qu; Ambar B Shrestha; Matthew K Thompson; Marco Bonizzoni; Charles Edwin Webster; Sherri A McFarland; Yonghyun Kim; Elizabeth T Papish
Journal:  Photochem Photobiol       Date:  2021-11-13       Impact factor: 3.421

Review 2.  Organometallic gold(I) and gold(III) complexes for lung cancer treatment.

Authors:  Juzheng Zhang; Yanping Li; Ronghao Fang; Wei Wei; Yong Wang; Jiamin Jin; Feng Yang; Jian Chen
Journal:  Front Pharmacol       Date:  2022-09-13       Impact factor: 5.988

3.  Bioinformatics analysis of C3 and CXCR4 demonstrates their potential as prognostic biomarkers in clear cell renal cell carcinoma (ccRCC).

Authors:  Jing Quan; Yuchen Bai; Yunbei Yang; Er Lei Han; Hong Bai; Qi Zhang; Dahong Zhang
Journal:  BMC Cancer       Date:  2021-07-15       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.